ASR Vermogensbeheer N.V. Sells 6,601 Shares of Thermo Fisher Scientific Inc. $TMO

ASR Vermogensbeheer N.V. trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.7% during the third quarter, Holdings Channel.com reports. The firm owned 110,191 shares of the medical research company’s stock after selling 6,601 shares during the period. Thermo Fisher Scientific accounts for approximately 0.6% of ASR Vermogensbeheer N.V.’s holdings, making the stock its 26th largest position. ASR Vermogensbeheer N.V.’s holdings in Thermo Fisher Scientific were worth $53,439,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of TMO. Vanguard Group Inc. boosted its position in Thermo Fisher Scientific by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 33,789,164 shares of the medical research company’s stock valued at $13,700,154,000 after buying an additional 309,207 shares during the last quarter. Norges Bank acquired a new position in shares of Thermo Fisher Scientific during the second quarter valued at $2,264,615,000. Franklin Resources Inc. boosted its holdings in Thermo Fisher Scientific by 11.3% in the second quarter. Franklin Resources Inc. now owns 4,897,546 shares of the medical research company’s stock valued at $1,985,759,000 after acquiring an additional 498,238 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Thermo Fisher Scientific by 2.6% in the second quarter. Charles Schwab Investment Management Inc. now owns 3,000,562 shares of the medical research company’s stock worth $1,216,612,000 after purchasing an additional 74,971 shares during the period. Finally, Flossbach Von Storch SE lifted its position in Thermo Fisher Scientific by 93.0% during the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after purchasing an additional 1,314,182 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 10,725 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the transaction, the executive vice president owned 18,731 shares of the company’s stock, valued at $11,238,600. This represents a 36.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Lisa P. Britt sold 1,058 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the sale, the vice president owned 13,087 shares in the company, valued at $7,698,558.62. This trade represents a 7.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 149,271 shares of company stock valued at $86,507,282. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $619.16 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The firm has a market capitalization of $232.62 billion, a PE ratio of 35.77, a P/E/G ratio of 4.11 and a beta of 0.91. The stock has a 50 day simple moving average of $586.34 and a 200 day simple moving average of $523.82. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $629.87.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the company earned $5.28 earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its Board of Directors has approved a stock repurchase program on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were paid a $0.43 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Evercore ISI reissued an “outperform” rating and set a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. The Goldman Sachs Group initiated coverage on Thermo Fisher Scientific in a research report on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price target on the stock. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a report on Wednesday, October 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $625.47.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.